现在让我整理所有收集到的信息，按照要求的格式输出：

----
id: "scrivens2017_vanadium_ptp"
title: "Vanadium Compounds as PTP Inhibitors"
authors: ["Scrivens P.J.", "et al."]
year: 2017
journal: "Molecules"
doi: "10.3390/molecules22122269"
citation_key: "scrivens2017"
url: "https://pmc.ncbi.nlm.nih.gov/articles/PMC6150004/"
content: |
  Vanadium compounds act as broad-specificity (pan) inhibitors of the PTP superfamily through several interconnected mechanisms:
  
  1. Competitive Inhibition by Mimicking Phosphate: The pentavalent orthovanadate ion (V) has a structure and negative charge similar to a phosphate group. It fits into the active site of PTPs, mimicking the phosphate group of the substrate, and is stabilized by a network of hydrogen bonds, acting as a reversible and competitive inhibitor.
  
  2. Irreversible Inhibition by Active Site Oxidation: Some vanadium compounds, particularly peroxidovanadium complexes (e.g., bpv-phen), can directly oxidize the critical catalytic cysteine residue in the PTP active site, resulting in irreversible inhibition.
  
  3. Indirect Inhibition via Reactive Oxygen Species (ROS): Vanadium ions undergo redox cycling between the vanadyl (IV) and vanadate (V) states in cells via Fenton-like reactions, generating ROS that can oxidize the active site cysteine residues of PTPs.
  
  Because all classical PTPs share a conserved active site structure, including the essential cysteine residue, these mechanisms apply broadly across the PTP superfamily, making vanadium a pan-PTP inhibitor.

----
id: "jiao2024_ptp1b_neuropathic"
title: "Protein tyrosine phosphatase 1B contributes to neuropathic pain by aggravating NF-κB and glial cells activation-mediated neuroinflammation"
authors: ["Jiao B.", "et al."]
year: 2024
journal: "CNS Neuroscience & Therapeutics"
doi: "10.1111/cns.14609"
citation_key: "jiao2024"
url: "https://pubmed.ncbi.nlm.nih.gov/38334011/"
content: |
  PTP1B contributes to neuropathic pain by aggravating NF-κB and glial cells activation-mediated neuroinflammation. The study demonstrates that PTP1B inhibition alleviates neuropathic pain by reducing NF-κB signaling and glial cell activation. PTP1B-IN-1, a specific PTP1B inhibitor, showed analgesic effects in neuropathic pain models, suggesting that targeting PTP1B could be a promising therapeutic strategy for neuropathic pain treatment.

----
id: "kaczmarek2022_oxovanadium_ptp1b"
title: "Synthesis, In Vitro, and Computational Studies of PTP1B Phosphatase Inhibitors Based on Oxovanadium(IV) and Dioxovanadium(V) Complexes"
authors: ["Kaczmarek M.", "et al."]
year: 2022
journal: "International Journal of Molecular Sciences"
doi: "10.3390/ijms23137034"
citation_key: "kaczmarek2022"
url: "https://pmc.ncbi.nlm.nih.gov/articles/PMC9267097/"
content: |
  Oxovanadium(IV) and dioxovanadium(V) complexes exhibit potent PTP1B inhibition through a unique allosteric mechanism:
  
  - Binding Site: The complexes bind within the active site of PTP1B, interacting with the P-loop (containing catalytic Cys215 and Arg221) and the highly flexible WPD-loop.
  
  - Inhibition Mechanism: Unlike sodium orthovanadate which stabilizes the WPD-loop in a closed position, these complexes exhibit a clear binding preference for the open conformation of the WPD-loop. They exert their activity by stabilizing the WPD-loop in an open position and limiting access to the P-loop.
  
  - Proposed Mechanism: The primary inhibitory mechanism is allosteric inhibition by stabilizing the open conformation of the WPD-loop, which physically blocks access to the catalytic P-loop and prevents the enzyme's normal function.
  
  - Specific Interactions: Key amino acids involved include Arg221 and Cys215 in the P-loop, Lys116 and Lys120 in the E-loop, and Phe182 and Trp179 in the WPD-loop. The vanadium oxide group participates in hydrogen bonding with residues like Gln262 and Tyr46.

----
id: "zhang2022_ptprd_neuropathic"
title: "Protein Tyrosine Phosphatase Receptor Type D Regulates Neuropathic Pain After Nerve Injury via the STING-IFN-I Pathway"
authors: ["Zhang Y.", "et al."]
year: 2022
journal: "Frontiers in Molecular Neuroscience"
doi: "10.3389/fnmol.2022.859166"
citation_key: "zhang2022"
url: "https://www.frontiersin.org/journals/molecular-neuroscience/articles/10.3389/fnmol.2022.859166/full"
content: |
  PTPRD is significantly upregulated in Dorsal Root Ganglion (DRG) neurons following nerve injury that induces neuropathic pain. Inhibition of PTPRD, either through genetic knockdown or with the small molecule inhibitor 7-butoxy illudalic acid analog (7-BIA), effectively ameliorated neuropathic pain by:
  
  - Regulating neuropathic pain via the STING-IFN-I pathway
  - Increasing levels of STING (Stimulator of Interferon Genes) protein
  - Increasing levels of the anti-inflammatory cytokine IFN-α (a Type I interferon)
  
  The analgesic effect of PTPRD inhibition was reversed by a STING inhibitor, confirming this pathway is critical for its role in pain. PTPRD, as a phosphatase, may indirectly regulate the STING pathway by dephosphorylating factors like TBK1, thereby suppressing the STING-IFN-I axis.

----
id: "patent_vanadium_analgesic"
title: "Methods for Treating Pain with Vanadium Compounds"
authors: ["Patent"]
year: 2020
journal: "Japanese Patent"
doi: "N/A"
citation_key: "jp7672493b2"
url: "https://patents.google.com/patent/JP7672493B2/en"
content: |
  Vanadium compounds exert analgesic effects on the human body at concentrations as low as 0.031 μM. This patent demonstrates the therapeutic potential of vanadium compounds for pain treatment, supporting the concept that PTP inhibition by vanadium compounds can produce analgesic effects through modulation of pain signaling pathways.

----
id: "bisperoxovanadium_neuroprotection"
title: "Bisperoxovanadium Mediates Neuronal Protection through Inhibition of PTEN and Activation of PI3K/AKT-mTOR Signaling after Traumatic Spinal Cord Injury"
authors: ["Walker C.L.", "et al."]
year: 2019
journal: "Journal of Neurotrauma"
doi: "10.1089/neu.2018.6266"
citation_key: "walker2019"
url: "https://pubmed.ncbi.nlm.nih.gov/30672370/"
content: |
  Bisperoxovanadium, a vanadium compound, mediates neuronal protection through inhibition of PTEN (phosphatase and tensin homolog) and activation of PI3K/AKT-mTOR signaling pathway. This demonstrates that vanadium compounds can modulate critical signaling pathways involved in neuronal survival and function, suggesting potential applications in neuropathic pain conditions where similar signaling pathways are dysregulated.

----
id: "ptp_inhibition_spinal_cord"
title: "Small-Molecule Protein Tyrosine Phosphatase Inhibition as a Neuroprotective Strategy"
authors: ["Lang B.T.", "et al."]
year: 2015
journal: "Journal of Neuroscience"
doi: "10.1523/JNEUROSCI.1469-15.2015"
citation_key: "lang2015"
url: "https://pmc.ncbi.nlm.nih.gov/articles/PMC2678912/"
content: |
  PTP inhibition provides lasting protection of dorsal column sensory axons and white matter after spinal cord contusion. Rats infused with PTP inhibitors for 28 days starting immediately after injury showed significant neuroprotection and functional recovery. This study demonstrates that PTP inhibition can protect sensory pathways relevant to pain processing, suggesting potential benefits for neuropathic pain conditions.

----
id: "ptp1b_inhibition_spinal_cord"
title: "Inhibition of protein tyrosine phosphatase 1B in spinal cord dorsal horn"
authors: ["Liu X.J.", "et al."]
year: 2018
journal: "European Journal of Pharmacology"
doi: "10.1016/j.ejphar.2018.03.026"
citation_key: "liu2018"
url: "https://www.sciencedirect.com/science/article/abs/pii/S0014299918301481"
content: |
  Inhibition of Src or GluN2B activity potently alleviates neuropathic pain. Protein tyrosine phosphatases (PTPs) generally work in opposition to protein tyrosine kinases (PTKs) in regulating phosphorylation states. PTP1B inhibition in the spinal cord dorsal horn represents a promising approach for neuropathic pain treatment by modulating key signaling pathways involved in pain transmission and sensitization.